Bay x 1005 attenuates atherosclerosis in apoE-LDLR - double knockout mice

• Autorzy: Jawien J. , Gajda M. , Olszanecki R. , Korbut R.
• Języki publikacji: EN

Abstrakty

EN

Recently, we have shown that MK-886 - an inhibitor of five lipoxygenase activating protein (FLAP) inhibits atherosclerosis in apolipoprotein E / LDL receptor - double knockout mice. We, therefore, wanted to find out if other FLAP inhibitor - BAYx1005 given at a dose of 1.88 mg per 100 mg of body weight per day during 16 weeks, could also attenuate atherogenesis. In apoE/LDLR - DKO mouse model BAYx1005 inhibited atherogenesis, measured both by "en face" method (23.84 ± 2.7% vs. 15.16 ± 1.4%) and "cross-section" method (497236 ± 31516 µm2 vs. 278107 ± 21824 µm2). This is the first report that shows the effect of BAYx1005 on atherogenesis in gene-targeted mice.

Słowa kluczowe

EN

pathogenesis; mouse; LDL receptor; mice; knockout mice; inflammatory disease; apolipoprotein; atherosclerosis

• Wydawca: -
• Czasopismo: Journal of Physiology and Pharmacology
• Rocznik: 2007
• Tom: 58
• Numer: 3
• Opis fizyczny: p.583-588,fig.,ref.

Twórcy

autor

Jawien J.

• Jagiellonian University School of Medicine, Grzegorzecka Str.16, 31-531 Krakow, Poland

autor

Gajda M.

autor

Olszanecki R.

autor

Korbut R.